Cancer

Jul 05, 2022

AstraZeneca’s Imfinzi Shows Positive Results; Novartis Announces Results of Tislelizumab; FDA Grants Orphan Drug Designation to Evorpacept; EU Approves Sanofi’s Xenpozyme; Bayer’s Kerendia Approves in China; FDA Breakthrough Therapy Designation to Talquetamab; FDA Puts Clinical Hold on Sanofi’s Tolebrutinib; FDA Rejects Spero’s Tebipenem

Jun 22, 2022

How is Nanomedicine Transforming the Dynamics of the Healthcare Industry?

Mar 31, 2022

Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies

Mar 16, 2022

Can Cannabinoids be an Effective Medicinal Substance?

Jan 12, 2022

Insights into the Evolving Landscape of Antibody-Drug Conjugate (ADC) & the Key Companies in the Segment

Jan 11, 2022

Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trails for NVL-520; Stryker acquires Vocera Communications

Jan 05, 2022

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Jan 04, 2022

Accutar’s Phase I clinical trial for AC0176; Bio-Thera’s cancer drug, BAT6005; Nykode’s Covid-19 vaccine trial; Heat Biologics acquires Elusys

Dec 13, 2021

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Therapies, Competitive Landscape and Impact of COVID-19

Aug 24, 2021

AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi

Newsletter/Whitepaper